Trial Profile

Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin; Insulin glargine
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms Lixibrain01

Most Recent Events

08 Jul 2020 Status changed from recruiting to discontinued.
03 Jul 2020 This trial has been completed in Germany as per European Clinical Trials Database
16 Apr 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com